Group 5D: HER2-low, HER2-0, & Triple Negative Breast Cancer

Poster #PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy.

Poster #PO1-25-12: Metformin enhances response to chemotherapy combined with immunotherapy in a triple negative breast cancer in vivo model.